HTGMQ vs. IDXG, NSTG, PRPO, CHEK, PMD, A, MTD, ILMN, WAT, and AVTR
Should you be buying HTG Molecular Diagnostics stock or one of its competitors? The main competitors of HTG Molecular Diagnostics include Interpace Biosciences (IDXG), NanoString Technologies (NSTG), Precipio (PRPO), Check-Cap (CHEK), Psychemedics (PMD), Agilent Technologies (A), Mettler-Toledo International (MTD), Illumina (ILMN), Waters (WAT), and Avantor (AVTR).
HTG Molecular Diagnostics (NASDAQ:HTGMQ) and Interpace Biosciences (NASDAQ:IDXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
In the previous week, Interpace Biosciences had 1 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 1 mentions for Interpace Biosciences and 0 mentions for HTG Molecular Diagnostics. HTG Molecular Diagnostics' average media sentiment score of 0.00 equaled Interpace Biosciences'average media sentiment score.
Interpace Biosciences received 319 more outperform votes than HTG Molecular Diagnostics when rated by MarketBeat users.
5.7% of Interpace Biosciences shares are owned by institutional investors. 2.6% of HTG Molecular Diagnostics shares are owned by insiders. Comparatively, 6.5% of Interpace Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Interpace Biosciences has higher revenue and earnings than HTG Molecular Diagnostics.
HTG Molecular Diagnostics has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Interpace Biosciences has a net margin of 2.26% compared to HTG Molecular Diagnostics' net margin of 0.00%. HTG Molecular Diagnostics' return on equity of 0.00% beat Interpace Biosciences' return on equity.
Summary
Interpace Biosciences beats HTG Molecular Diagnostics on 9 of the 11 factors compared between the two stocks.
Get HTG Molecular Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HTGMQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HTGMQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HTGMQ vs. The Competition
HTG Molecular Diagnostics Competitors List
Related Companies and Tools
